Progression-Free Survival
FIG 4. · Panel A
Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yann Christinat, Intidhar Labidi-Galy, Liza Ho, Sophie Clément, Catherine Genestie, Jalid Sehouli, Saverio Cinieri, Antonio Gonzalez-Martin, Vassiliki Kolovetsiou-Kreiner, Keiichi Fujiwara, Toon Von Gorp, Germana Tognon, Sakari Hietanen, Viola Heinzelmann-Schwarz, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Thomas A McKee
JCO Precis Oncol 9 e2400825
PURPOSE: The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase inhibitors has been demonstrated. Its performance with respect to overall survival (OS) has not been assessed yet. METHODS: Using the final results of the PAOLA-1/ENGOT-ov25 phase III clinical trial with a median follow-up of 5 years, we evaluated the Geneva HRD test on 468 samples as part of the ENGOT HRD European Initiative. Results were evaluated in terms of final PFS and OS in the olaparib + bevacizumab and placebo + bevacizumab arms and compared with the Myriad MyChoice HRD test. RESULTS: Final PFS was consistent with previously published data and confirmed the predictive value of the Geneva HRD test with a hazard ratio (HR) of 0.41 (95% CI, 0.30 to 0.57) for HRD-positive patients. The results for OS showed a HR of 0.56 (95% CI, 0.37 to 0.85) for HRD-positive patients and 1.6 (95% CI, 1.1 to 2.3) for HRD-negative patients. These results are consistent with those observed with the Myriad test, including the negative OS trend in the HRD-negative subgroup treated with olaparib + bevacizumab (HR, 1.2 [95% CI, 0.83 to 1.8]). A subgroup analysis of patients with intermediate HRD scores showed that the normalized large-scale state transition score used by the Geneva HRD test had both predictive and prognostic value. CONCLUSION: The Geneva HRD test predicts PFS and OS benefit from olaparib + bevacizumab. The potential detrimental effect of olaparib + bevacizumab on OS in the HRD-negative population is hypothesis-generating and needs to be confirmed prospectively.
2 个 Figure · 4 个 KM 面板
PFS and OS in the placebo + bevacizumab arm with respect to the nLST score divided in three categories (HRD-negative: nLST <15; HRD-positive–mid: 15 ≤ nLST < 20; HRD-positive–high: nLST ≥20). (A) PFS and (B) OS. HRD, homologous recombination deficiency; nLST, normalized large-scale state transition; OS, overall survival; PFS, progression-free survival.
FIG 4. · Panel A
Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. · Panel B
Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kaplan-Meier OS curves for the HRD-positive subpopulation, according to the Geneva HRD test, with respect to the BRCA mutation status (given by the Myriad test). (A) BRCA mutated and (B) BRCA wild-type. HR, hazard ratio; HRD, homologous recombination deficiency; OS, overall survival.
这些图片未产生 KM 曲线结果,不在主页面重复展示。